M&A / Deals Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors pharminent April 9, 2026
M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic pharminent April 8, 2026
Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment pharminent April 7, 2026
Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer pharminent April 6, 2026
Regulatory S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD pharminent March 31, 2026
Other S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD pharminent March 31, 2026
Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD pharminent March 30, 2026
Other S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC pharminent March 27, 2026
